The July/August issue of NeuroPerspective features our midyear appraisal of the CNS therapeutics sector, including capsule reviews of more than 100 neuro-oriented companies. It also includes a comprehensive review of Spinal Cord Injury, for which a confluence of regenerative pharmacotherapy and sophisticated neurorehabilitation techniques appears poised to offer the prospect of significant functional improvement in the lives of individuals with SCI. In that vein, the Company Review is of BioAxone, which is approaching the 2018 completion of a Phase IIb in SCI, in conjunction with its partner, Vertex Pharmaceuticals. Sidebars include commentary on the potential importance of huntingtin isoforms in the treatment of HD, and some ‘too good to be true’ claims for the use of suramin in Autism. 48 pages.
